
Full text loading...
This mini-review will provide an overview on the recent design principles and structure-activity-relationship of β-selective thyroid hormone receptor (TR) agonists. The prospects for the treatment of metabolic diseases as dyslipidemia with TRβ-selective ligands are considerable enough so as to avoid cardiovascular acceleration mediated through TRα.